Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.6M | $25.6M | $17.1M | $7.1M | $7.8M | $4.6M | $4.0M | $4.4M |
| Cost of revenue | $9.3M | $13.2M | $8.8M | $2.7M | $1.6M | $2.0M | $2.7M | $2.3M |
| Gross profit | $13.3M | $12.4M | $8.3M | $4.4M | $6.2M | $2.6M | $2.5M | $2.0M |
| Gross margin | 59.0% | 48.6% | 48.6% | 61.5% | 79.0% | 56.8% | 62.7% | 46.8% |
| R&D | $1.2M | $3.4M | $3.3M | $4.6M | $8.0M | $13.2M | $22.9M | $83.1M |
| Operating income | −$14.3M | −$22.1M | −$1.1M | −$17.2M | −$21.1M | −$44.9M | −$69.7M | −$126.6M |
| EBITDA | −$15.9M | −$20.6M | −$4.3M | −$18.2M | −$20.2M | −$41.7M | −$66.1M | −$124.2M |
| Net income | −$17.3M | −$24.2M | −$5.8M | −$15.3M | −$22.9M | −$44.3M | −$67.3M | −$123.3M |
| Net margin | -76.4% | -94.6% | -34.1% | -215.8% | -294.0% | -966.0% | -1678.0% | -2822.5% |
| EPS (diluted) | -6.78 | -7.93 | -0.99 | -2.58 | -3.09 | -3.32 | -4.31 | -6.09 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-4.02 | $-4.02–$-4.02 | 1 |
| 2027 | $14M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds AMEUF.
No tracked institution reports a position in AMEUF as of their last filing.
No one on the platform has traded AMEUF yet.
| $132M |
| — |
| EPRXFEupraxia Pharmaceuticals Inc. | $3.04 | -6.17% | $108M | — |
| GREHGreen Rain Energy Holdings Inc. | $0.01 | -1.60% | $107800 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 3.0× sales vs its 44.9× historical median P/S.
Fair value ≈ $84.66 · price $5.70 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.